Literature DB >> 8824972

Recurrence of urinary tract infection in a primary care setting: analysis of a 1-year follow-up of 179 women.

R Ikäheimo1, A Siitonen, T Heiskanen, U Kärkkäinen, P Kuosmanen, P Lipponen, P H Mäkelä.   

Abstract

In a prospective study, 179 adult women (age range, 17-82 years) were followed up for 12 months after an index episode of community-acquired cystitis caused by Escherichia coli. Episodes of symptomatic urinary tract infection (UTI) were recorded, and urinary isolates were compared with the index episode isolate; 147 UTI episodes were detected during the follow-up. Of these episodes, 131 were classified as recurrences occurring at least 1 month after the index episode; 44% of the patients had recurrences. A history of UTI increased the risk of recurrence; only 11.8% of the 17 patients without previous episodes of UTI had at least one recurrence, while 47.5% of those with previous episodes had at least one recurrence (OR, 6.8; univariate logistic regression). E. coli caused 78% of the recurrent episodes. Phenotypic and genotypic analysis of E. coli strains showed that one-third of the recurrences were caused by the index episode strain, which could persist and cause recurrences throughout the 1-year follow-up period. The prevalence of adhesins or other identified virulence factors for UTI among the recurrence strains was identical to that among the index episode strains. The presence of these factors did not affect the risk of recurrence but did increase the likelihood that the index episode strain would persist and cause recurrent episodes of UTI.

Entities:  

Mesh:

Year:  1996        PMID: 8824972     DOI: 10.1093/clinids/22.1.91

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  93 in total

1.  Distinguishing the contribution of type 1 pili from that of other QseB-misregulated factors when QseC is absent during urinary tract infection.

Authors:  Maria Kostakioti; Maria Hadjifrangiskou; Corinne K Cusumano; Thomas J Hannan; James W Janetka; Scott J Hultgren
Journal:  Infect Immun       Date:  2012-06-04       Impact factor: 3.441

2.  Persistence of uropathogenic Escherichia coli in the face of multiple antibiotics.

Authors:  Matthew G Blango; Matthew A Mulvey
Journal:  Antimicrob Agents Chemother       Date:  2010-03-15       Impact factor: 5.191

Review 3.  Invasion of Host Cells and Tissues by Uropathogenic Bacteria.

Authors:  Adam J Lewis; Amanda C Richards; Matthew A Mulvey
Journal:  Microbiol Spectr       Date:  2016-12

4.  The predictive utility of prior positive urine culture in children with recurrent urinary tract infections.

Authors:  Reut Doyev; Efrat Ben-Shalom; Orli Megged
Journal:  Eur J Pediatr       Date:  2019-11-26       Impact factor: 3.183

Review 5.  Covert operations of uropathogenic Escherichia coli within the urinary tract.

Authors:  Jean M Bower; Danelle S Eto; Matthew A Mulvey
Journal:  Traffic       Date:  2005-01       Impact factor: 6.215

Review 6.  [Treatment and prophylaxis of recurrent urinary tract infections].

Authors:  B Banas; B K Krämer
Journal:  Internist (Berl)       Date:  2005-12       Impact factor: 0.743

7.  Mechanisms of uropathogenic Escherichia coli persistence and eradication from the urinary tract.

Authors:  Indira U Mysorekar; Scott J Hultgren
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-12       Impact factor: 11.205

Review 8.  Urinary tract infections in adult general practice patients.

Authors:  Eva Hummers-Pradier; Michael M Kochen
Journal:  Br J Gen Pract       Date:  2002-09       Impact factor: 5.386

9.  Escherichia coli from urine of female patients with urinary tract infections is competent for intracellular bacterial community formation.

Authors:  Corinne K Garofalo; Thomas M Hooton; Steven M Martin; Walter E Stamm; Joseph J Palermo; Jeffrey I Gordon; Scott J Hultgren
Journal:  Infect Immun       Date:  2006-10-30       Impact factor: 3.441

10.  Lipopolysaccharide Domains Modulate Urovirulence.

Authors:  Lizath M Aguiniga; Ryan E Yaggie; Anthony J Schaeffer; David J Klumpp
Journal:  Infect Immun       Date:  2016-10-17       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.